Compare Redwire Corporation (RDW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Sana Biotechnology Inc — how do they compare? Redwire Corporation trades at $9.47 (market cap $2.44B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Redwire Corporation is far larger — about 2.9× Sana Biotechnology Inc's market cap, and Redwire Corporation is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Sana Biotechnology Inc for 23 Days on average.
| RDW | SANA | |
|---|---|---|
Market Cap | $2.44B | $836.71M |
Volume | 11,053,212 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $25.90 | $5.92 |
52-Week Low | $5.06 | $2.68 |
Typical Hold Time | 18 Days | 23 Days |
Enterprise Value | $1.97B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $9.53, down 6.93% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, while revenue grew to $335.38M in 2025. Recent positive developments include a $981M Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data centers.
Despite strong analyst support (80% buy ratings) and a $14.88 price target representing 56% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents a high-risk opportunity for investors betting on space infrastructure growth, but requires careful monitoring of profitability improvements and execution on contract wins.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
